3-氯-4-甲基噻吩-2-羧肼 | 175137-12-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 中文名称: 3-氯-4-甲基噻吩-2-羧肼
• 英文名称: 3-chloro-4-methyl-2-thiophenecarboxylic acid hydrazide
• 英文别名: 3-chloro-4-methylthien-2-ylcarboxylic acid hydrazide；3-Chloro-4-methylthiophene-2-carbohydrazide
• CAS: 175137-12-9
• 化学式: C₆H₇ClN₂OS
• 分子量: 190.653
• InChiKey: COSDURBTTAEVMV-UHFFFAOYSA-N

物化性质

• 熔点：
  130 °C
• 密度：
  1.415±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  83.4
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  3-氯-4-甲基噻吩-2-羧肼 、 1-cyclopentyl-4,5-dihydro-3-ethyl-7-methylthio-1H-pyrazolo[3,4-c]pyridine 在 吡啶 作用下， 反应 8.0h， 以78%的产率得到5-(3-Chloro-4-methylthiophen-2-yl)-12-cyclopentyl-10-ethyl-3,4,6,11,12-pentazatricyclo[7.3.0.02,6]dodeca-1(9),2,4,10-tetraene
  参考文献：
  名称：

  SAR of a Series of 5,6-Dihydro-(9H)-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-α]pyridines as Potent Inhibitors of Human Eosinophil Phosphodiesterase

  摘要：

  The potency and physical properties of a previously reported 7-oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine series of human eosinophil phosphodiesterase inhibitors were improved by tying the lactam moiety into a triazolo ring. The resulting 5,6-dihydro-(9H)-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-alpha]pyridine series provided nonionizable analogs with melting point properties suitable for micronization. Substitution at the 3-position of the 5,6-dihydro-(9H)-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-alpha]pyridine tricycle led to a 2-thienyl analog, 19 (tofimilast), a potent PDE4 inhibitor with low oral bioavailability and no emesis-associated behaviors in ferrets at plasma concentrations up to 152 ng/mL.

  DOI：

  10.1021/jm060904g

文献信息

• Substituted Arylimidazolone and Triazolone as Inhibitors of Vasopressin Receptors
  申请人：Meier Heinrich

  公开号：US20090312381A1

  公开（公告）日：2009-12-17

  The present application relates to novel, substituted 4-arylimidazol-2-ones and 5-aryl-1,2,4-triazolones, processes for the production thereof, the use thereof alone or in combinations for the treatment and/or prevention of diseases and the use thereof for the production of medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular diseases.

  本申请涉及新颖的取代的4-芳基咪唑-2-酮和5-芳基-1,2,4-三唑酮，其生产方法，单独或组合使用以治疗和/或预防疾病，以及用于生产治疗和/或预防疾病的药物，特别是用于治疗和/或预防心血管疾病。
• Comparison of affinity ranking by target-directed dynamic combinatorial chemistry and surface plasmon resonance
  作者：Priska Frei、Marleen Silbermann、Tobias Mühlethaler、Xiaohua Jiang、Oliver Schwardt、Rachel Hevey、Beat Ernst

  DOI：10.24820/ark.5550190.p010.913

  日期：——

  Target-directed dynamic combinatorial chemistry (tdDCC) is a powerful method to screen ligands for pharmacologically relevant targets. Generating a dynamic library from reversibly reacting building blocks in the presence of a target protein leads to the amplification of the most potent library constituents. In previous studies on tdDCC, these compounds were identified in a qualitative “hit/no-hit”-manner

  靶向动态组合化学 (tdDCC) 是一种有效的方法来筛选药理学相关靶标的配体。在目标蛋白存在的情况下，通过可逆反应构建块生成动态库会导致最有效的库成分放大。在之前对 tdDCC 的研究中，这些化合物以定性的“命中/未命中”方式被鉴定。然而，扩增程度与文库成分亲和力之间的精确关系尚未得到评估。为了研究扩增-亲和力关系，我们比较了 tdDCC 实验，采用可逆酰腙形成和细菌粘附素 FimH 作为靶标，通过表面等离子体共振确定文库成分的亲和力。
• Substituted arylimidazolone and triazolone as inhibitors of vasopressin receptors
  申请人：Bayer Pharma Aktiengesellschaft

  公开号：US08084481B2

  公开（公告）日：2011-12-27

  The present application relates to novel, substituted 4-arylimidazol-2-ones and 5-aryl-1,2,4-triazolones, processes for the production thereof, the use thereof alone or in combinations for the treatment and/or prevention of diseases and the use thereof for the production of medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular diseases.

  本申请涉及新颖的取代的4-芳基咪唑-2-酮和5-芳基-1,2,4-三唑酮，其生产过程，它们的单独或组合使用用于治疗和/或预防疾病以及用于制造治疗和/或预防疾病的药物，特别是用于治疗和/或预防心血管疾病的药物。
• SUBSTITUTED ARYLIMIDAZOLONE AND TRIAZOLONE AS INHIBITORS OF VASOPRESSIN RECEPTORS
  申请人：Meier Heinrich

  公开号：US20130005704A1

  公开（公告）日：2013-01-03

  The present application relates to novel, substituted 4-arylimidazol-2-ones and 5-aryl-1,2,4-triazolones, processes for the production thereof, the use thereof alone or in combinations for the treatment and/or prevention of diseases and the use thereof for the production of medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular diseases.

  本申请涉及新型取代的4-芳基咪唑-2-酮和5-芳基-1,2,4-三唑酮，其生产过程，其单独或联合用于治疗和/或预防疾病的用途以及用于生产用于治疗和/或预防疾病的药物的用途，特别是用于治疗和/或预防心血管疾病。
• US8084481B2
  申请人：——

  公开号：US8084481B2

  公开（公告）日：2011-12-27